In 2023, Roche announced that it has strengthened its research and innovation efforts by expanding its partnership with Janssen Biotech to develop companion diagnostics for targeted therapies. With the latest agreement expansion, Roche and Janssen intend to increase opportunities to collaborate on precision medicine projects including a variety of companion diagnostic technologies such as immunohistochemistry, digital pathology, next generation sequencing, polymerase chain reaction and immunoassays.
In August 2023, Thermo Fisher Scientific announced that it had acquired CorEvitas, LLC from Audax Private Equity for USD 912.5 million. CorEvitas is a leading provider of regulatoryally validated, realworld evidence for approved medical treatments and therapy.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 4851
Published Date: Jan 17, 2024
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The growing cases of HAI and growth strategies by market players are some of the major factors anticipated to drive the growth of the blood culture tests market.
The market is anticipated to attain a CAGR of ~9.82% over the forecast period, i.e., 2024-2036.